Fed. Circ. Backs PTAB's Nixing Of Illumina DNA Patent Claims
The Federal Circuit on Friday affirmed a Patent Trial and Appeal Board decision that barred biomedical technology company Illumina from adding amended claims to two DNA sequencing patents, agreeing that the...To view the full article, register now.
Already a subscriber? Click here to view full article